Renadyl is under clinical development by Kibow Biotech and currently in Phase III for Chronic Kidney Disease (Chronic Renal Failure). According to GlobalData, Phase III drugs for Chronic Kidney Disease (Chronic Renal Failure) have a 62% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Renadyl’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Renadyl is under development for the treatment of chronic kidney disease. It is a consortia of live therapeutic (LBT) comprising of 3 probiotic strains: Streptococcus thermophilus (KB19), Lactobacillus acidophilus (KB27), and Bifidobacterium longum (KB31). It is administered through oral route as capsule fomulation.
Kibow Biotech overview
Kibow Biotech is a biotechnology company that offers dietary supplements. The company develops and commercializes scientifically-formulated and clinically-tested probiotic dietary supplements. It offers products such as Kibow flora, renadyl, and azodyl. Kibow Biotech’s renadyl product is a patented and proprietary probiotics dietary supplement. The company’s azodyl treats dog kidney failure and cat kidney failures; renadyl a natural supplement for kidney problems; Kibow fortis is used to manage digestive health and general wellness; and Kibow flora, used to boost immune system that include probiotics. It markets its products in the US, Argentina, Canada, Mexico, and Nigeria. Kibow Biotech is headquartered in Newtown Square, Pennsylvania, the US.
For a complete picture of Renadyl’s drug-specific PTSR and LoA scores, buy the report here.